Your browser doesn't support javascript.
loading
Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia.
Zheng, Fang-Yuan; Lu, Ai-Dong; Zuo, Ying-Xi; Jia, Yue-Ping; Wu, Jun; Zhang, Le-Ping.
Afiliação
  • Zheng FY; Peking University People's Hospital, Department of Pediatrics, Beijing, 100044, China.
  • Lu AD; Peking University People's Hospital, Department of Pediatrics, Beijing, 100044, China.
  • Zuo YX; Peking University People's Hospital, Department of Pediatrics, Beijing, 100044, China.
  • Jia YP; Peking University People's Hospital, Department of Pediatrics, Beijing, 100044, China.
  • Wu J; Peking University People's Hospital, Department of Pediatrics, Beijing, 100044, China.
  • Zhang LP; Peking University People's Hospital, Department of Pediatrics, Beijing, 100044, China. Electronic address: zhangleping@pkuph.edu.cn.
Leuk Res ; 95: 106405, 2020 08.
Article em En | MEDLINE | ID: mdl-32590107
ABSTRACT

PURPOSE:

To investigate the effect of tyrosine kinase inhibitors (TKIs) on the statural growth in children with acute lymphoblastic leukemia (ALL).

METHODS:

We retrospectively collected data from 344 children with ALL younger than 17 years old at diagnosis identified in pediatric department of Peking University People's Hospital. The children were divided into three groups conventional chemotherapy group, imatinib group and dasatinib group. Height was expressed as standard deviation score(HtSDS). In the three groups, we compared the HtSDS and △HtSDS at the start of treatment and during follow-up period and also compared the adult height and median parental height(MPH). We further compared the HtSDS classified by age and gender in imatinib group. At last, univariate analysis was used to analyze the influencing factors on the deceleration of height growth by imatinib.

RESULTS:

There were 298 children in conventional chemotherapy group, 39 in imatinib group and 7 in dasatinib group. In imatinib group, the mean HtSDS of children at follow-up time was significantly lower than that at the start of treatment (P < 0.05), regardless of age and gender. In imatinib group, the decrease of HtSDS in girls was more obvious than in boys(P = 0.031). The HtSDS gradually decreased in the first and the second year in imatinib group. After discontinuation of imatinib, the HtSDS had no obvious change. Multivariate analysis showed that the HtSDS at the start of imatinib was negatively correlated with severe growth impairment on imatinib therapy. The HtSDS in dasatinib group and conventional chemotherapy group maintained a high degree of consistency.

CONCLUSION:

Imatinib can affect growth velocity in children with ALL, regardless of age and gender. With the discontinuation of imatinib, the inhibitory effect will not continue. The lower HtSDS at the start of imatinib therapy, the more obvious effect of imatinib on growth impairment will be, and the effect will be more obvious in girls than boys.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estatura / Inibidores de Proteínas Quinases / Leucemia-Linfoma Linfoblástico de Células Precursoras / Mesilato de Imatinib / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estatura / Inibidores de Proteínas Quinases / Leucemia-Linfoma Linfoblástico de Células Precursoras / Mesilato de Imatinib / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article